Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Front Opens in First-Line Ovarian Cancer Market: GSK’s Zejula Vs. AZ’s Lynparza

Executive Summary

Two new PARP inhibitor studiesGSK’s PRIMA and AstraZeneca/Merck & Co.’s PAOLA-1  – are set to widen the ovarian cancer market after they reported highly positive first-line results in advanced patients at ESMO.

You may also be interested in...



AZ's Lynparza Shines Again In Prostate Cancer Study

With a PDUFA date fast approaching, AstraZeneca has presented more data from the PROfound study, this time showing that Lynparza improved OS compared to hormonal therapies in men with advanced castration-resistant prostate cancer with BRCA1/2 or ATM mutations.

Lynparza/Recentin Combo Fails In Phase III PSR Ovarian Cancer

Lynparza will weather the failure of the Phase III GY004 study, but VEGF inhibitor Recentin’s future looks even less certain; other studies of the combination continue.

Keeping Track: Two Novel Migraine Drugs Highlight Busy Week For US FDA Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID052006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel